Skip to main content

Peyronie Disease Responds to New Medical Treatment


May 30, 2012 — Collagenase Clostridium histolyticum (CCh) alleviates many symptoms of Peyronie disease, according to the findings of a phase 2b randomized, double-blind, placebo-controlled trial.
Martin Gelbard, MD, from Urology Associates Medical Group in Burbank, California, and colleagues published their findings in the June 2012 issue of the Journal of Urology.
The authors note that there is a need for additional nonsurgical treatments for Peyronie disease. "Surgery is the standard of care for moderate to severe cases of [Peyronie disease] unresponsive to medical therapy," they write. "However, surgery is only recommended for patients with sexual dysfunction in the stable phase of disease since complications include penile shortening, sensory change, recurrent penile curvature and [erectile dysfunction]."
To assess the efficacy of CCh, the authors recruited 147 patients from 12 American sites. They stratified patients by degree of penile curvature (30 - 60° or >60°) and randomly assigned them for treatment with either CCh or placebo (3:1 randomization), with or without penile plaque modeling (1:1 randomization). CCh treatment improved curvature by 29.7% (mean change, −16.3° ± 14.65°) compared with an improvement of 11% (mean change, −5.4 ± 13.8°) in the placebo group (P = .001).
For each treatment cycle, patients received 2 injections of CCh (0.58 mg or 10,000 U) or placebo, separated by 24 to 72 hours, and treatment was repeated after 6 weeks for a maximum of 6 treatment cycles. The authors measured penile length and curvature using calipers and assessed the effects of Peyronie disease on patient quality of life and penile function, using the Peyronie disease patient-reported outcome (PD-PRO) and International Index of Erectile Function (IIEF) questionnaires, respectively.
Among patients who underwent penile plaque modeling, patients treated with CCh exhibited a 32.4% improvement in penile curvature (mean change, − 17.5° ± 15.3°) compared with a 2.5% worsening (mean change, 0.6° ± 13.2°) in the placebo group (P < .001). Conversely, among nonmodeled patients, no difference was observed in the change in penile curvature between the CCh and placebo groups (27.1% vs 27.9%, respectively).
Among the modeled patients, those treated with CCh had a significantly higher mean improvement in the PD-PRO symptom bother domain score compared with placebo (mean change, −3.6° vs −0.1°, respectively; P = .004), whereas no change was observed among nonmodeled patients (−1.5° vs −1.5°, respectively). Moreover, among the modeled patients, CCh treatment was associated with a significant mean improvement in the IIEF overall sexual satisfaction score compared with placebo (P = .04).
Adverse events were significantly more common among CCh-treated patients, including bruising (P < .001), edema (P < .001), pain (P < .001), contusion (P = .07), penile pain (P = .07), and penile edema (P = .07). However, most adverse events were mild to moderate in severity. The limitations of the study included the use of a fixed prostaglandin E1 dose to induce erection before measurements and the learning curve of the investigators regarding the injection technique.
The authors indicate that additional studies are underway to better clarify the efficacy of this treatment. "[The r]esults suggest that CCh should be considered a viable treatment option" for patients with Peyronie disease, they write. "Placebo controlled, phase 3 studies of [Peyronie disease]...are currently ongoing to provide additional safety and efficacy information."
John P. Mulhall, MD, from the Memorial Sloan-Kettering Cancer Center in New York City, indicated that this agent may soon be available for clinical use. "This early phase study demonstrates promising results for this intralesional agent," Dr. Mulhall told Medscape Medical News by email. "Phase III trials with 600 men enrolled will be completed soon, and it is hoped that the data will be presented to the [US Food and Drug Administration] in 2012 with hopes for an approval in 2013."
Dr. Gelbard has a financial interest and/or other relationship with Auxilium and Biospecifics. One coauthor has a financial interest and/or other relationship with Allergan, Auxilium, American Medical Systems, and Repros Therapeutics. Three coauthors are employed by Auxilium. One coauthor has a financial interest and/or other relationship with Auxilium, Coloplast, Lilly, Astellas, Pfizer, and American Medical Systems. Dr. Mulhall has disclosed no relevant financial relationships.

Comments

  1. Unknown13 November 2013 at 02:15

    This the excellent post which I have seen and it helped me a lot , Thanks for sharing it!!
    peyronies treatment

    ReplyDelete

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more